Clinical trial · Interventional
Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML
A Single-arm, Single-center Clinical Trial Evaluating the Efficacy and Safety of a Regimen Combining Chidamide With Venetoclax, Azacitidine, and Homoharringtonine in the Treatment of Intermediate- to High-risk Fit AML Patients
NCT07643636CI-TRIAL-00115296not yet recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to explore a superior first-line induction remission regimen by incorporating Chidamide into the modified VAH chemotherapy combined with targeted therapy regimen, leveraging its dual epigenetic modulation mechanism.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| AML (Acute Myeloid Leukemia) | Acute Myeloid Leukemia | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chidamide (Chi)+VAH | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Chidamide , Venetoclax, Azacitidine, Homoharringtonine
- interventionNames
- Drug: Chidamide (Chi)+VAH
Primary outcomes (1)
- measure
- Composite Complete Remission Rate （CR+CRi）
- timeFrame
- the First Induction Cycle （28days）
Secondary outcomes (6)
- measure
- MRD negativity rate after the first induction cycle
- timeFrame
- 28 days
- measure
- Composite CR/CRi rate after the second induction cycle
- timeFrame
- 56 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: 1. Newly diagnosed fit-AML patients classified per the World Health Organization (WHO) classification criteria. 2. Age ranging from 18 to 60 years, no restriction on gender. 3. No prior anti-AML systemic therapy after AML diagnosis; cytoreductive treatment (e.g., hydroxyurea or cytarabine at a daily dose \<1.0 g) is permitted as exception. 4. Estimated overall survival ≥12 weeks. 5. Eastern Cooperative Oncology Group (ECOG) performance status ≤3 points. 6. Renal function: calculated creatinine clearance (CrCl) ≥30 mL/min. 7. Hepatic function: alanine aminotransferase (ALT) \<5× upper limit of normal (ULN); total bilirubin \<3× ULN. 8. Able to provide written informed consent and understand as well as comply with all study-specified procedures. Exclusion Criteria: 1. Patients stratified as favorable-risk AML defined by NCCN Guidelines 2022, including cytogenetic aberrations: t(8;21)(q22;q22.1); RUNX1-RUNX1T1, inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11. 2. Confirmed acute promyelocytic leukemia (APL). AML complicated with central nervous system (CNS) leukemia infiltration. 3. Cardiac function exceeding NYHA functional class II. 4. Confirmed human immunodeficiency virus (HIV) infection or other uncontrolled clinically significant comorbidities, including but not limited to: * Uncontrolled or active systemic infection (viral, bacterial or fungal); ② Concurrent second primary malignancy requiring urgent clinical intervention. 6\. Patients unable to receive oral chidamide and/or venetoclax administration. 7. Known hypersensitivity to any investigational product. 8. Pregnant or breastfeeding female subjects. 9. Inability to understand or adhere to the study protocol requirements. 10.Subjects deemed unsuitable for enrollment at the investigator's discretion
References
Publications (0)
Data not yet available
No reference posted for this study.